Bibliographic record

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised…

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D…. The Lancet 2019

§1Bibliographic record

Authors: Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I
Title: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Source: The Lancet
Year: 2019
Volume, issue, pages: 394(10193):121–130
Digital object identifier: 10.1016/S0140-6736(19)31149-3
PubMed identifier: 31189511
Record type: Journal article
Institute identifier: CEI-BR-033

Table 1. Documents in the Institute set that cite this record.

Document	Series
Monograph: Dulaglutide	Compound monograph
Trial abstract: REWIND	Trial abstract
Synthesis: Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists	Evidence synthesis
Synthesis: Cardiovascular benefit in primary compared with secondary prevention	Evidence synthesis
Synthesis: Dulaglutide in type 2 diabetes mellitus: effect on the anchor outcome	Evidence synthesis
Synthesis: Dulaglutide in atherosclerotic cardiovascular disease and…	Evidence synthesis
Synthesis: Dulaglutide in type 2 diabetes mellitus: tolerability and…	Evidence synthesis
Synthesis: Dulaglutide in atherosclerotic cardiovascular disease and…	Evidence synthesis
Synthesis: Dulaglutide in type 2 diabetes mellitus: durability of effect	Evidence synthesis
9 citing documents.

dulaglutide cardiovascular REWIND

Compound Evidence Institute · CEI-BR-033 · https://compoundevidence.com/bibliography/gerstein2019/ · retrieved 30 July 2026